Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | AHCY | P23526 | 1/20 | 0.49 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969651 | 0.89 | ADORA2A (0.84) | ADORA2AEGFRPI4KAPI4K2BPI4K2A | |
| Methylglyoxal SCHEMBL6013421 | 0.84 | ADORA2A (0.78) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Methylglyoxal SCHEMBL6013418 | 0.81 | ADORA2A (0.76) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1230786 | 0.81 | ADORA2A (1.00) | ADORA2AEGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL14028468 | 0.76 | ADORA2A (0.59) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Methylglyoxal SCHEMBL6013415 | 0.76 | AHCY (0.64) | ADORA2AEGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL17297723 | 0.75 | ADCY5 (0.74) | ADORA2AEGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL6045746 | 0.74 | ADCY5 (0.74) | ADORA2AEGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL14027563 | 0.74 | ADORA2A (0.59) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13882135 | 0.73 | ADORA2A (0.66) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258612-A1 | CFTR channel modulators | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258612-A1 | CFTR channel modulators | CFTR, SCNN1B, SCNN1A | ADORA2A 606/4885EGFR 2614/4885PI4KA 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.